Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$5.21
-0.4%
$4.71
$1.00
$7.00
$46.55M0.67172,775 shs4,846 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.69
+2.4%
$1.59
$1.03
$2.41
$52.72M-0.53423,646 shs103,742 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$1.59
-2.2%
$1.99
$1.50
$28.80
$12.16M5.4285,035 shs67,068 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.49
-5.1%
$1.67
$1.12
$8.40
$44.35M-0.677.84 million shs435,724 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
0.00%-3.52%+13.02%+30.58%+283.09%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%+9.74%+4.32%+1.20%-13.55%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00%-6.76%-22.30%-52.83%-93.94%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
0.00%-4.49%+23.14%-40.40%-60.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
3.1279 of 5 stars
3.35.00.00.03.81.70.0
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.9541 of 5 stars
3.55.00.00.02.80.00.6
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.6091 of 5 stars
0.03.00.00.02.41.70.0
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
2.6558 of 5 stars
3.82.00.00.02.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.50
Moderate Buy$12.00130.33% Upside
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$4.50166.27% Upside
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00
N/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
3.50
Strong Buy$15.00906.71% Upside

Current Analyst Ratings Breakdown

Latest ERNA, ATHE, ATNM, and TELO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$1.04 per shareN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$535K22.73N/AN/A$0.58 per share2.73
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-$12.54MN/A0.00N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$44.54M-$8.31N/AN/A-7,652.75%N/A-682.08%N/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$16.53M-$0.54N/AN/AN/AN/A-5,240.54%-1,694.68%N/A

Latest ERNA, ATHE, ATNM, and TELO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.08-$0.17-$0.09-$0.17N/AN/A
8/13/2025Q2 2025
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A-$0.61N/A-$0.61N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/A
3.84
N/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
1.81
0.21
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
0.75
0.75
CompanyEmployeesShares OutstandingFree FloatOptionable
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
108.87 million5.43 millionNot Optionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
107.67 million7.56 millionNo Data
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
129.76 millionN/AN/A

Recent News About These Companies

TELO Makes Progress Toward Human Trials
Telomir Flat on Trial Data Release
TELO Announces Another Important Breakthrough

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$5.21 -0.02 (-0.38%)
Closing price 08/15/2025 03:55 PM Eastern
Extended Trading
$5.21 0.00 (0.00%)
As of 08/15/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.69 +0.04 (+2.42%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$1.68 0.00 (-0.30%)
As of 08/15/2025 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$1.58 -0.04 (-2.16%)
Closing price 08/15/2025 03:59 PM Eastern
Extended Trading
$1.64 +0.05 (+3.47%)
As of 08/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Telomir Pharmaceuticals stock logo

Telomir Pharmaceuticals NASDAQ:TELO

$1.49 -0.08 (-5.10%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$1.48 -0.01 (-0.67%)
As of 08/15/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.